Oric Pharmaceuticals, Inc. — Director's Dealing 2023

Dec 20, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2023-12-15

Reporting Person: Piscitelli Dominic (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-15	Common Stock	M	14042	$0.00	Disposed	89091	Direct
2023-12-15	Common Stock	S	5282	$8.5835	Disposed	83809	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-15	Restricted Stock Unit	$	M	6042	Disposed		Common Stock (6042)	Direct
2023-12-15	Restricted Stock Unit	$	M	8000	Disposed		Common Stock (8000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of ORIC Pharmaceuticals, Inc. (the "Issuer") Common Stock.

F2: Includes an aggregate of 7,764 shares of Common Stock acquired under the Issuer's 2020 Employee Stock Purchase Plan.

F3: Represents the number of shares sold to cover the tax withholding obligations in connection with the vesting of RSUs and does not represent a discretionary sale by the Reporting Person.

F4: Represents the weighted average share price of an aggregate total of 5,282 shares sold in the price range of $8.57 to $8.756 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F5: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2022, December 15, 2023 and December 15, 2024.

F6: 1/3 of the RSUs subject to the award shall vest on each of December 15, 2023, December 15, 2024 and December 15, 2025.